Evidence map›Paper›PMID 40534672›Full record

ArticleACS pharmacology & translational science2025

Spotlight on Glycan Pairing: The Generation and Impact of Monoclonal Antibody Asymmetrical Fc N‑Glycan Pairs on Fc Receptor Interaction.

Maximilian Meudt, Julia Baumeister, Erik M F Machal, Matthias J Knape, Boris Mizaikoff, Sybille Ebert, Frank Rosenau, Michaela Blech, Fabian Higel

Abstract read
In one paragraph

Article in ACS pharmacology & translational science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Maximilian MeudtAnalytical Development Biologicals, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss 88400, Germany.ORCID https://orcid.org/0009-0004-1863-0008
Julia BaumeisterAnalytical Development Biologicals, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss 88400, Germany.
Erik M F MachalAnalytical Development Biologicals, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss 88400, Germany.
Matthias J KnapeAnalytical Development Biologicals, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss 88400, Germany.
Boris MizaikoffInstitute of Analytical and Bioanalytical Chemistry, Ulm University, Ulm 89069, Germany.ORCID https://orcid.org/0000-0002-5583-7962
Sybille EbertInstitute of Applied Biotechnology, Biberach University of Applied Sciences, Biberach an der Riss 88400, Germany.
Frank RosenauInstitute of Pharmaceutical Biotechnology, Ulm University, Ulm 89069, Germany.ORCID https://orcid.org/0000-0002-9297-6419
Michaela BlechAnalytical Development Biologicals, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss 88400, Germany.
Fabian HigelGlobal CMC Experts NBE, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss 88400, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Monoclonal antibodies' Fc N-glycans play a crucial role in their therapeutic efficacy, as they influence effector functions through Fc receptor binding. However, the impact of asymmetrical Fc glyco-pairs is often overlooked in assessing Fc receptor binding and effector functions. This study addresses this gap by generating pure asymmetrical Fc glyco-pairs and evaluating their Fc receptor binding properties, thereby providing a comprehensive understanding of the impact of Fc N-glycans. Utilizing redox pairing and affinity chromatography, homogeneously asymmetrical Fc glyco-pairs were generated, and their interaction properties toward Fcγ receptors IIIa, IIa, IIb, and I were determined by surface plasmon resonance. The results underscore the importance of considering the apparent glycan distribution of Fc N-glycans as glycan pairing was found to individually influence Fc receptor binding. Notably, single afucosylation significantly increased the affinity for FcγRIIIa, while the effect of galactosylation was detectable but less pronounced. Galactosylation, however, played a crucial role in FcγRIIa binding, with asymmetrical galactosylation being sufficient for the whole effect. In contrast, for FcγRIIb, afucosylation was more important, while galactosylation played a minor role. Furthermore, glycosylation-dependent Fc-FcγRI complex stability differences could be resolved, challenging the commonly held belief that this interaction is glycosylation independent.

Indexed as

biotherapeuticseffector functionFcγ receptorglycan pairingmonoclonal antibodyN-glycosylation

Identifiers

PMID40534672
PMCPMC12171887

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.